DEFGEN Oral Suspension contains Deflazacort, a corticosteroid used primarily in the treatment of Duchenne muscular dystrophy (DMD) in children aged 2 years and older. DMD is a genetic disorder characterized by progressive muscle weakness and degeneration. DEFGEN works by suppressing abnormal immune responses and reducing inflammation caused by the overproduction of cytokines—chemicals responsible for tissue damage in autoimmune diseases. By binding to immune cells and modulating their activity, DEFGEN helps manage autoimmune conditions and slows the progression of muscle deterioration. It is also beneficial in managing inflammatory conditions such as asthma, arthritis, and psoriasis. Its liquid form makes it ideal for pediatric patients who have difficulty swallowing tablets, offering accurate dosing and ease of administration.